Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
Status:
Not yet recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
This is a phase II study testing the combination of pembrolizumab with lenvatinib, a
multi-kinase inhibitor that has activity against vascular endothelial growth factor receptors
1-3 (VEGFR1-3), fibroblast growth factor receptors 1-4 (FGFR1-4), ret protooncogene (RET),
platelet-derived growth factor receptor-alpha (PDGFR-alpha) and KIT (a stem cell factor
receptor), and letrozole, a non-steroidal aromatase inhibitor, in advanced hormone receptor
(HR) positive human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC)
that has progressed on/after standard endocrine therapy.